Literature DB >> 16792965

[The role of the rotavirus vaccine in childhood vaccination schedules].

F Giménez Sánchez1, F Martinón Torres, E Bernaola Iturbe, M Baca Cots, F de Juan Martín, J Díez Delgado, M Garcés Sánchez, J A Gómez Campderá, J Picazo, V Pineda Solas.   

Abstract

Rotavirus is the leading cause of diarrhea in infants. In developed countries, this infection leads to considerable morbidity with a high number of hospitalizations and medical interventions in the winter season, giving rise to substantial medical and social costs. In developing countries, rotavirus is a major cause of mortality in infants due to dehydration, with an estimated 600.000 deaths or more per year worldwide. A vaccine that is easy administrated, safe and with high efficacy would be the ideal means to reduce the burden of this disease and its high economic and social cost and to decrease the number of deaths in low-income countries. Recently, the results of two well-designed clinical trials with a large number of subjects have been reported. Both studies, which used different vaccines, reported high efficacy in the prevention of severe gastroenteritis and hospitalizations caused by rotavirus. When these vaccines become available in Europe, a reduction in hospitalizations, medical consultations, and days of work lost can be expected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792965     DOI: 10.1157/13089923

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  3 in total

1.  An estimation of indirect costs caused by acute rotavirus gastroenteritis in a Galician area, Spain.

Authors:  Federico Martinón-Torres; Marta Bouzón-Alejandro; Maria López-Sousa; Lorenzo Redondo-Collazo; Santiago Almeida-Agudín; Consuelo Astorgano-Fernández; José María Martinón-Sánchez
Journal:  Eur J Pediatr       Date:  2007-03-16       Impact factor: 3.183

2.  Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.

Authors:  Javier Diez-Domingo; Nuria Lara Suriñach; Natalia Malé Alcalde; Lourdes Betegón; Nathalie Largeron; Mélanie Trichard
Journal:  BMC Public Health       Date:  2010-08-10       Impact factor: 3.295

3.  Prospective evaluation of indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST study.

Authors:  Marta Bouzón-Alejandro; Lorenzo Redondo-Collazo; Juan Manuel Sánchez-Lastres; Nazareth Martinón-Torres; José María Martinón-Sánchez; Federico Martinón-Torres
Journal:  BMC Pediatr       Date:  2011-09-14       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.